144 related articles for article (PubMed ID: 27179128)
1. Metabolism and Disposition of Pan-Genotypic Inhibitor of Hepatitis C Virus NS5A Ombitasvir in Humans.
Shen J; Serby M; Surber B; Lee AJ; Ma J; Badri P; Menon R; Kavetskaia O; de Morais SM; Sydor J; Fischer V
Drug Metab Dispos; 2016 Aug; 44(8):1148-57. PubMed ID: 27179128
[TBL] [Abstract][Full Text] [Related]
2. Metabolism and Disposition of Hepatitis C Polymerase Inhibitor Dasabuvir in Humans.
Shen J; Serby M; Reed A; Lee AJ; Menon R; Zhang X; Marsh K; Wan X; Kavetskaia O; Fischer V
Drug Metab Dispos; 2016 Aug; 44(8):1139-47. PubMed ID: 27179126
[TBL] [Abstract][Full Text] [Related]
3. Metabolism and Disposition of the Hepatitis C Protease Inhibitor Paritaprevir in Humans.
Shen J; Serby M; Reed A; Lee AJ; Zhang X; Marsh K; Khatri A; Menon R; Kavetskaia O; Fischer V
Drug Metab Dispos; 2016 Aug; 44(8):1164-73. PubMed ID: 27179127
[TBL] [Abstract][Full Text] [Related]
4. Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection.
Gentile I; Buonomo AR; Borgia G
Expert Rev Anti Infect Ther; 2014 Sep; 12(9):1033-43. PubMed ID: 25074011
[TBL] [Abstract][Full Text] [Related]
5. Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers.
Polepally AR; King JR; Ding B; Shuster DL; Dumas EO; Khatri A; Chiu YL; Podsadecki TJ; Menon RM
Clin Pharmacokinet; 2016 Aug; 55(8):1003-14. PubMed ID: 26895022
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment.
Khatri A; Menon RM; Marbury TC; Lawitz EJ; Podsadecki TJ; Mullally VM; Ding B; Awni WM; Bernstein BM; Dutta S
J Hepatol; 2015 Oct; 63(4):805-12. PubMed ID: 26070406
[TBL] [Abstract][Full Text] [Related]
7. Clinical Pharmacokinetics of Ombitasvir.
Badri PS; Shuster DL; Dutta S; Menon RM
Clin Pharmacokinet; 2017 Oct; 56(10):1103-1113. PubMed ID: 28229375
[TBL] [Abstract][Full Text] [Related]
8. Drug-Drug Interaction of Omeprazole With the HCV Direct-Acting Antiviral Agents Paritaprevir/Ritonavir and Ombitasvir With and Without Dasabuvir.
Polepally AR; Dutta S; Hu B; Podsadecki TJ; Awni WM; Menon RM
Clin Pharmacol Drug Dev; 2016 Jul; 5(4):269-77. PubMed ID: 27310328
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir.
Badri P; Dutta S; Coakley E; Cohen D; Ding B; Podsadecki T; Bernstein B; Awni W; Menon R
Am J Transplant; 2015 May; 15(5):1313-22. PubMed ID: 25708713
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.
Khatri A; Dutta S; Wang H; Podsadecki T; Trinh R; Awni W; Menon R
Clin Infect Dis; 2016 Apr; 62(8):972-9. PubMed ID: 26740513
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.
Lawitz E; Makara M; Akarca US; Thuluvath PJ; Preotescu LL; Varunok P; Morillas RM; Hall C; Mobashery N; Redman R; Pilot-Matias T; Vilchez RA; Hézode C
Gastroenterology; 2015 Oct; 149(4):971-80.e1. PubMed ID: 26170136
[TBL] [Abstract][Full Text] [Related]
12. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir.
Menon RM; Badri PS; Wang T; Polepally AR; Zha J; Khatri A; Wang H; Hu B; Coakley EP; Podsadecki TJ; Awni WM; Dutta S
J Hepatol; 2015 Jul; 63(1):20-9. PubMed ID: 25646891
[TBL] [Abstract][Full Text] [Related]
13. Effects of omeprazole and ritonavir on absorption and elimination of the hepatitis C virus NS5A inhibitor GSK2336805 in healthy adults.
Adkison KK; Jones LS; Lou Y; Gan J; Wilfret DA
Clin Pharmacol Drug Dev; 2014 Sep; 3(5):338-45. PubMed ID: 27129005
[TBL] [Abstract][Full Text] [Related]
14. Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir.
King JR; Dutta S; Cohen D; Podsadecki TJ; Ding B; Awni WM; Menon RM
Antimicrob Agents Chemother; 2016 Feb; 60(2):855-61. PubMed ID: 26596948
[TBL] [Abstract][Full Text] [Related]
15. Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir.
Badri PS; Dutta S; Wang H; Podsadecki TJ; Polepally AR; Khatri A; Zha J; Chiu YL; Awni WM; Menon RM
Antimicrob Agents Chemother; 2016 Jan; 60(1):105-14. PubMed ID: 26459906
[TBL] [Abstract][Full Text] [Related]
16. Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.
Klibanov OM; Gale SE; Santevecchi B
Ann Pharmacother; 2015 May; 49(5):566-81. PubMed ID: 25680759
[TBL] [Abstract][Full Text] [Related]
17. Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C.
Flisiak R; Flisiak-Jackiewicz M
Expert Rev Gastroenterol Hepatol; 2017 Jun; 11(6):559-567. PubMed ID: 28317409
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic Evaluation of Darunavir Administered Once or Twice Daily in Combination with Ritonavir or the Three-Direct-Acting Antiviral Regimen of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults Coinfected with Hepatitis C and Human Immunodeficiency Viruses.
King JR; Khatri A; Trinh R; Viani RM; Ding B; Zha J; Menon R
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27919899
[TBL] [Abstract][Full Text] [Related]
19. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.
Hézode C; Asselah T; Reddy KR; Hassanein T; Berenguer M; Fleischer-Stepniewska K; Marcellin P; Hall C; Schnell G; Pilot-Matias T; Mobashery N; Redman R; Vilchez RA; Pol S
Lancet; 2015 Jun; 385(9986):2502-9. PubMed ID: 25837829
[TBL] [Abstract][Full Text] [Related]
20. Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial.
Welzel TM; Asselah T; Dumas EO; Zeuzem S; Shaw D; Hazzan R; Forns X; Pilot-Matias T; Lu W; Cohen DE; Feld JJ
Lancet Gastroenterol Hepatol; 2017 Jul; 2(7):494-500. PubMed ID: 28416221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]